CLINICAL TRIALS PROFILE FOR OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN
✉ Email this page to a colleague
505(b)(2) Clinical Trials for Omeprazole And Clarithromycin And Amoxicillin
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Combination | NCT03124199 ↗ | Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection | Completed | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Phase 3 | 2014-02-01 | Background: A progressive decrease in Helicobacter pylori eradication rates has been described over the years, so new combinations of antibiotics for treatment are needed. Aim: To evaluate the efficacy and safety of the addition of rifaximin to standard triple therapy (omeprazole, amoxicillin and clarithromycin) for the eradication of H. pylori. Methods: Independent prospective pilot clinical trial (EUDRA CT: 2013-001080-23). Forty consecutive adult patients were included with H. pylori infection, dyspeptic symptoms and naive to eradication treatment. A full blood test was performed in the first 5 patients included to evaluate the safety of the treatment. H. pylori eradication was confirmed with urea breath test at least 4 weeks after the end of treatment. Treatment: Rifaximin 400 mg/8 h, clarithromycin 500 mg/12 h, amoxicillin 1 g/12 h, and omeprazole 20 mg/12 h for 10 days. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Omeprazole And Clarithromycin And Amoxicillin
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00002682 ↗ | Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach | Completed | National Cancer Institute (NCI) | Phase 2 | 1995-08-10 | RATIONALE: Antibiotic therapy and antacids are used to treat Helicobacter pylori infection of the stomach. These treatments may also have an effect on gastric MALT lymphoma of the stomach. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy with amoxicillin, clarithromycin, tetracycline, and metronidazole plus antacids in patients with MALT lymphoma of the stomach. |
| NCT00002682 ↗ | Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach | Completed | M.D. Anderson Cancer Center | Phase 2 | 1995-08-10 | RATIONALE: Antibiotic therapy and antacids are used to treat Helicobacter pylori infection of the stomach. These treatments may also have an effect on gastric MALT lymphoma of the stomach. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy with amoxicillin, clarithromycin, tetracycline, and metronidazole plus antacids in patients with MALT lymphoma of the stomach. |
| NCT00003151 ↗ | Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma | Completed | University of Glasgow | Phase 2 | 1997-09-01 | RATIONALE: Antibiotics may stop the growth of Helicobacter pylori which may be associated with gastric lymphoma. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy in treating patients with low grade gastric lymphoma that has not been previously treated. |
| NCT00003151 ↗ | Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma | Completed | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 | 1997-09-01 | RATIONALE: Antibiotics may stop the growth of Helicobacter pylori which may be associated with gastric lymphoma. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy in treating patients with low grade gastric lymphoma that has not been previously treated. |
| NCT00149084 ↗ | Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori | Unknown status | Yokoyama Foundation for Clinical Pharmacology | Phase 3 | 2003-04-01 | The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy. |
| NCT00149084 ↗ | Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori | Unknown status | Hamamatsu University | Phase 3 | 2003-04-01 | The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy. |
| NCT00206440 ↗ | Nexium Study To Suppress Nausea During Chemotherapy | Terminated | AstraZeneca | Phase 3 | 2005-08-01 | This study will look at a drug called esomeprazole, the newest PPI, as a way to further reduce the amount of nausea and vomiting seen in breast cancer patients receiving adriamycin or epirubicin chemotherapy. Esomeprazole may help protect the gut lining from the stomach acid and thus lessen the nausea and vomiting. If patients have less stomach sickness, they may be able to enjoy their daily routines much more while they are getting chemotherapy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Omeprazole And Clarithromycin And Amoxicillin
Condition Name
Clinical Trial Locations for Omeprazole And Clarithromycin And Amoxicillin
Trials by Country
Clinical Trial Progress for Omeprazole And Clarithromycin And Amoxicillin
Clinical Trial Phase
Clinical Trial Sponsors for Omeprazole And Clarithromycin And Amoxicillin
Sponsor Name
| Sponsor Name for Omeprazole And Clarithromycin And Amoxicillin | |
| Sponsor | Trials |
| Tehran University of Medical Sciences | 4 |
| Hamamatsu University | 1 |
| Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | 1 |
| [disabled in preview] | 4 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
